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ABSTRACT: 
Mycobacterium tuberculosis is a significant source of global morbidity and mortality. Moxifloxacin 
and other fluoroquinolones are important therapeutics for the treatment of tuberculosis, particularly 
multi-drug resistant infections. In order to guide the development of new quinolone-based agents, it 
is critical to understand the basis of drug action against M. tuberculosis gyrase and how mutations 
in the enzyme cause resistance. Therefore, we characterized interactions of fluoroquinolones and 
related drugs with wild-type gyrase and enzymes carrying mutations at GyrAA90 and GyrAD94. M. 
tuberculosis gyrase lacks a conserved serine that anchors a water-metal ion bridge that is critical for 
quinolone interactions with other bacterial type II topoisomerases. Despite the fact that the serine is 
replaced by an alanine (GyrAA90) in M. tuberculosis gyrase, the bridge still forms and plays a 
functional role in mediating quinolone-gyrase interactions. Clinically relevant mutations at GyrAA90 
and GyrAD94 cause quinolone resistance by disrupting the bridge-enzyme interaction, thereby 
decreasing drug affinity. Fluoroquinolone activity against wild-type and resistant enzymes can be 
enhanced by the introduction of specific groups at the C7 and C8 positions. By dissecting 
fluoroquinolone-enzyme interactions, we determined that an 8-methyl-moxifloxacin derivative 
induces high levels of stable cleavage complexes with wild-type gyrase and two common resistant 
enzymes, GyrAA90V and GyrAD94G. 8-Methyl-moxifloxacin was ~2 times more potent than 
moxifloxacin against wild-type M. tuberculosis gyrase and displayed higher activity against the 
mutant enzymes than moxifloxacin did against wild-type gyrase. This chemical biology approach to 
defining drug-enzyme interactions has the potential to identify novel drugs with improved activity 
against tuberculosis. 
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SIGNIFICANCE STATEMENT: 
Moxifloxacin and other fluoroquinolone antibacterials are important anti-tuberculosis therapeutics. 
Fluoroquinolones kill Mycobacterium tuberculosis, the causative agent of tuberculosis, by 
increasing levels of DNA breaks generated by gyrase, an essential type II topoisomerase that 
regulates DNA topology. As fluoroquinolone usage in anti-tuberculosis regimens is becoming more 
pronounced, understanding the basis of drug-gyrase interactions and resistance is becoming more 
important. Using a mechanism-based chemical biology approach, our work identified critical drug 
features that mediate fluoroquinolone interactions with M. tuberculosis gyrase and determined the 
biochemical basis for fluoroquinolone resistance caused by the most common clinical mutations in 
gyrase. These findings allowed us to identify a moxifloxacin derivative that displays enhanced 
activity against wild-type gyrase and maintains high activity against clinically relevant resistant 
enzymes.  
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Tuberculosis is a major cause of morbidity and mortality on a global scale and is second only to 
HIV/AIDS as the most prolific killer due to a single infectious agent (1). According to the World 
Health Organization, 9 million people were diagnosed with tuberculosis in 2013, and 1.5 million 
died from the disease (1). The standard treatment regimen for tuberculosis is a 6-month course that 
includes a combination of rifampin, isoniazid, pyrazinamide, and ethambutol (2, 3). However, 
fluoroquinolones are becoming more important in the treatment of tuberculosis and are routinely 
used in multi-drug resistant cases and in patients who are intolerant of first-line therapy (2, 4, 5). 
Furthermore, moxifloxacin (a newer generation fluoroquinolone) has shown promising results as a 
potential first-line agent as part of the PaMZ regimen (PA-824, moxifloxacin, and pyrazinamide), 
which currently is in clinical trials (6). 
 Fluoroquinolones are broad-spectrum antibacterials that act by increasing levels of DNA strand 
breaks generated by type II topoisomerases (7-12). Most bacterial species encode two type II 
enzymes, gyrase and topoisomerase IV (8, 10, 12-14). In these species, gyrase regulates the 
superhelical density of the bacterial chromosome and removes torsional stress that is generated 
ahead of DNA replication forks and transcription complexes, and topoisomerase IV primarily 
unknots and untangles DNA (11, 15, 16). Mycobacterium tuberculosis, the causative agent of 
tuberculosis, is unusual in that it encodes only gyrase (17). As a result, this enzyme displays 
functional properties of both type II topoisomerases (18).  
 Recent structural (19) and functional (20, 21) studies with topoisomerase IV indicate that 
quinolones interact with bacterial type II enzymes primarily through a water-metal ion bridge. This 
bridge is formed by a divalent metal ion that is chelated by the C3/C4 keto acid of the drug and 
stabilized by four water molecules (19). Two of these water molecules are coordinated by a 
conserved serine and acidic residue (located four positions downstream) in the A subunit of the 
enzyme. Substitutions in the residues that anchor the bridge are the most prevalent cause of 
quinolone resistance (10-13, 22-27). In most species, the serine is mutated far more often than the 
acidic residue.   
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 In contrast to most bacterial species, M. tuberculosis gyrase contains an alanine (A90) in place 
of the conserved serine. This situation raises the issue of whether the water-metal ion bridge can be 
formed or plays a role in mediating quinolone activity in this species. However, the fact that 
mutations at A90 and the acidic residue (D94) are associated with clinical quinolone resistance in 
M. tuberculosis (28) suggests that the bridge contributes to quinolone function.  
 Fluoroquinolones are commonly prescribed for community-acquired pneumonia that is later 
diagnosed as pulmonary tuberculosis (29). This prior treatment is associated with an increased 
incidence of fluoroquinolone-resistant disease (30, 31). As the use of fluoroquinolones in treating 
tuberculosis is becoming more pronounced, understanding the basis of drug-gyrase interactions and 
resistance is becoming more important. Therefore, we analyzed the interactions of fluoroquinolones 
and related compounds with wild-type and resistant mutant M. tuberculosis gyrase. Results indicate 
that the water-metal ion bridge is partially functional in wild-type gyrase and that the most common 
resistance mutations cause a decrease in bridge-mediated drug affinity for the enzyme. In contrast to 
other species (32, 33), quinolone interactions within the gyrase-cleaved DNA complex depend more 
heavily on substituents at C7 and C8. Based on an analysis of structure-activity relationships at 
these two positions, we identified fluoroquinolones that display significantly improved activity 
against wild-type and resistant M. tuberculosis gyrase as compared to moxifloxacin.  
Results and Discussion 
Gyrase is a heterotetramer comprised of two subunits, GyrA (which contains the active site tyrosine 
that cleaves and ligates DNA) and GyrB (which contains the ATPase and metal-binding domains) 
(8, 10, 12-14). To characterize interactions between quinolones and M. tuberculosis gyrase, we 
utilized wild-type enzyme and GyrAA90S, GyrAA90V, GyrAD94G, and GyrAD94H. Amino acid residues 
A90 and D94 occur at the positions that, by sequence homology, are predicted to anchor the water-
metal ion bridge if it is used to mediate quinolone-enzyme interactions in this species (19-21). The 
GyrAA90V, GyrAD94G, and GyrAD94H proteins contain three of the most common mutations 
associated with quinolone resistance in clinical isolates of M. tuberculosis (28). The GyrAA90S 
protein replaces the alanine found in the wild-type enzyme with a serine, which is the residue that 
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serves as a bridge anchor in most bacterial type II topoisomerases. The positions of GyrAA90 and 
GyrAD94 relative to bound quinolones are described in the accompanying paper by Blower et al. 
(34). 
 The GyrB subunit of M. tuberculosis gyrase was reannotated based on sequence alignments 
with 50 other bacterial species (35). It is now believed that the start codon is GTG (rather than 
ATG), which results in a protein that is 675 amino acids in length, rather than 714 (28). The 
experiments described in this paper used GyrB that reflects this updated annotation. 
Enzymatic Activities of Wild-Type and Quinolone-Resistant Mutant M. tuberculosis Gyrase. 
Before analyzing fluoroquinolone action against the wild-type and GyrAA90S, GyrAA90V, GyrAD94G, 
and GyrAD94H mutant M. tuberculosis gyrase proteins, we determined baseline DNA supercoiling 
and cleavage activities for the enzymes in the absence of drugs (Figure 1). Each mutant enzyme 
maintained high DNA supercoiling activity and in the presence of Ca2+ (used to increase baseline 
levels of enzyme-mediated DNA scission) cleaved DNA at least as well as wild-type gyrase. Thus, 
quinolone resistance does not correlate with a loss of baseline activity for any of the mutant 
enzymes examined. 
Effects of Fluoroquinolones and Related Compounds on DNA Cleavage Mediated by Wild-
Type and Fluoroquinolone-Resistant Mutant M. tuberculosis Gyrase. The first set of 
experiments compared the ability of ciprofloxacin and moxifloxacin to induce DNA cleavage by 
wild-type gyrase and the mutant enzymes (Figure 2, top). The two drugs generated similar levels of 
cleavage with the wild-type enzyme. In contrast, moxifloxacin maintained higher activity against 
the GyrAA90V, GyrAD94G, and GyrAD94H mutant proteins. As shown previously, the D94G and D94H 
mutations caused a higher level of fluoroquinolone resistance than the A90V mutation (36, 37). 
 The above findings are consistent with the hypothesis that fluoroquinolones interact with wild-
type M. tuberculosis gyrase through a water-metal ion bridge that is anchored primarily by D94. To 
investigate this possibility, the activity of ciprofloxacin and moxifloxacin against GyrAA90S was 
examined. The inclusion of the serine residue in place of the alanine provides the potential to 
reconstitute a fully functional bridge. As seen in Figure 2 (top), both fluoroquinolones displayed 
dramatically higher activity against GyrAA90S than they did against wild-type gyrase: drug potency 
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(i.e., drug concentration required to induce 50% maximal DNA cleavage) was ~5-fold higher and 
levels of cleavage at 100 µM were ~2-fold higher. Collectively, these findings suggest that there is 
sufficient conservation of structure such that M. tuberculosis gyrase is capable of using a water-
metal ion bridge to mediate fluoroquinolone-enzyme interactions. This conclusion is supported by 
the structural studies in the accompanying paper by Blower et al. (34). 
 Quinazolinediones are fluoroquinolone-like compounds that lack the C3/C4 keto acid required 
to chelate metal ions. In several other species, quinazolinediones containing a 3’-
(aminomethyl)pyrrolidinyl [3’-(AM)P] (or a related) group at C7 maintain activity against enzymes 
containing mutations that disrupt the water-metal ion bridge by forming binding interactions 
primarily through the C7 substituent (20, 21, 32, 38-42). As seen in Figure 2 (middle, left), the 
activity of 8-methyl-3’-(AM)P-dione is unaffected by mutations that could disrupt or strengthen the 
water-metal ion bridge in M. tuberculosis gyrase. The activity of 8-methyl-3’-(AM)P-FQ (the 
fluoroquinolone version of this quinazolinedione) is unaffected by bridge-disrupting mutations but 
is enhanced upon the introduction of the serine residue at position 90 (Figure 2, middle, right). Once 
again, these findings support the hypothesis that clinically relevant fluoroquinolones interact with 
M. tuberculosis gyrase through the water-metal ion bridge and that D94 likely mediates a partial 
bridging interaction in the absence of the upstream serine. 
 Fluoroquinolones that have a C8 substituent generally display better activity against clinical 
tuberculosis isolates than do derivatives with a C8-H (43, 44). Therefore, 3’-(AM)P-
quinazolinedione and -fluoroquinolone derivatives that contained a C8-H were used to examine the 
influence of the C8 substituent on drug activity (Figure 2, bottom). The activity of 8-H-3’-(AM)P-
dione was markedly decreased against all of the enzymes, confirming that the C8 methyl group 
plays an important role in mediating the activity of these compounds. The activity of 8-H-3’-
(AM)P-FQ also decreased with each enzyme as compared to the C8-methyl version of this 
fluoroquinolone. The relative activity of 8-H-3’-(AM)P-FQ correlated with the capacity of each 
enzyme to anchor the water-metal ion bridge.  
 Taken together, the above findings strongly suggest that wild-type M. tuberculosis gyrase 
partially supports the water-metal ion bridge and that the bridge and the C7 and C8 substituents play 
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important roles in supporting quinolone activity. Therefore, the contributions of these three drug 
features to quinolone interactions and activity were analyzed in greater detail. 
Role of the Water-Metal Ion Bridge in Facilitating Quinolone Activity Against M. tuberculosis 
Gyrase. To determine whether quinolone interactions with M. tuberculosis gyrase are mediated by 
the water-metal ion bridge, Mg2+ titrations were carried out to assess the effects of A90 mutations 
on the metal ion concentration required to support DNA cleavage induced by ciprofloxacin (Figure 
3, left). The amino acid at this position plays a critical role in anchoring the water-metal ion bridge 
in other bacterial type II enzymes (20, 21, 33). Results with wild-type gyrase were compared to 
those of mutant enzymes containing a serine or a valine in place of the alanine at position 90. The 
GyrAA90S mutant enzyme, which contains the conserved serine residue found in most other bacterial 
type II enzymes and greatly enhances fluoroquinolone activity (see Figure 2), required a lower 
concentration of Mg2+ to achieve half-maximal and maximal levels of quinolone-induced DNA 
cleavage. In marked contrast, the GyrAA90V mutant enzyme, which causes quinolone resistance (see 
Figure 2), required a higher concentration of Mg2+ to achieve half-maximal and maximal levels of 
quinolone-induced DNA cleavage.  
 These results demonstrate that the amino acid at position 90 affects the affinity of the divalent 
metal ion that is chelated by the quinolone and indicate that the water-metal ion bridge is a point of 
contact between quinolones and M. tuberculosis gyrase. It is likely that the alanine at position 90 in 
wild-type gyrase, while not serving as a bridge anchor, still allows D94 to anchor the bridge. 
However, because M. tuberculosis gyrase has only one available amino acid to anchor the bridge, 
fluoroquinolone interactions are weaker than seen with species that encode two amino acid bridge 
anchors (20, 21, 33). Substitution of A90 with the larger valine may cause quinolone resistance by 
interfering with the ability of water molecules to coordinate properly with the Mg2+ or by impeding 
D94 interactions with the bridge. 
 As a control for the above experiment, the effects of A90 mutations on the Mg2+ requirement 
for DNA cleavage induced by 8-methyl-3’-(AM)P-dione (which does not require a metal ion for 
enzyme interactions) were determined. In contrast to results with ciprofloxacin, similar levels of 
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Mg2+ were required to achieve half-maximal and maximal cleavage with all three enzymes (Figure 
3, right).  
 In other bacterial type II topoisomerases, mutations in bridge-anchoring residues that partially 
disrupt the water-metal ion bridge often restrict the variety of metal ions that can be used to form 
the bridge (21, 33). Therefore, we examined the ability of a second divalent metal ion, Mn2+, to 
support ciprofloxacin activity against wild-type gyrase and enzymes with mutations at position 90 
(Figure 4). With GyrAA90S, which has a fully intact bridge, the level of ciprofloxacin-induced DNA 
cleavage was unaffected by the substitution of this metal ion for Mg2+. However, with wild-type 
gyrase, which has a partially disrupted bridge, ciprofloxacin activity was decreased ~2-fold. 
Furthermore, with GyrAA90V, which has a more severely disrupted bridge, the quinolone displayed 
no ability to enhance enzyme-mediated DNA cleavage in the presence of Mn2+. Therefore, relative 
levels of resistance seen with enzymes containing mutations in bridge-anchoring residues can be 
altered by the metal ion used to support this interaction. A stronger water-metal ion bridge allows 
more latitude with metal ion requirements. 
 The water-metal ion bridge has been shown to play critical roles in mediating fluoroquinolone 
binding and positioning, but its predominant role appears to differ across species. With B. anthracis 
topoisomerase IV, it primarily acts as a binding contact (20, 21). However, with E. coli 
topoisomerase IV, it has little effect on drug affinity and is believed to properly position the drug in 
a manner that promotes DNA cleavage (33). Therefore, to determine whether the water-metal ion 
bridge plays a major role in drug-enzyme binding in M. tuberculosis gyrase, we used a competition 
approach and examined the effects of ciprofloxacin on DNA cleavage induced by 10 µM 8-methyl-
3’-(AM)P-dione in two enzymes with impaired bridge function (GyrAA90V and GyrAD94G). In an 
enzyme with optimal bridge function (GyrAA90S), the fluoroquinolone and quinazolinedione display 
similar abilities to induce gyrase-mediated DNA cleavage and act with comparable potencies (see 
Figure 2 left, top and middle). 
 With both resistant mutant enzymes (GyrAA90V and GyrAD94G), ciprofloxacin competed poorly 
against the bridge-independent quinazolinedione (Figure 5). Even at a 10-fold molar excess of the 
quinolone, levels of DNA cleavage decreased by only ~25%. This finding implies that impaired 
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bridge function decreases the affinity of ciprofloxacin for the enzyme at least an order of magnitude 
and strongly suggests that in M. tuberculosis gyrase the water-metal ion bridge plays a critical role 
in mediating quinolone binding. 
Enhancing Fluoroquinolone Activity Against Wild-type and Resistant M. tuberculosis Gyrase 
by Modifying Substituents at C7 and C8. Previous studies (43, 44) have shown that 
fluoroquinolones containing a substituent at C8 (in particular, a methoxy group) display higher 
activity against M. tuberculosis and related organisms. However, the basis for the effects of C8 
substitutions on fluoroquinolone activity against M. tuberculosis gyrase is not well understood. 
Therefore, we compared the activities of fluoroquinolones containing a C8–H, –methyl, or –methoxy 
group against the wild-type and resistant enzymes. Two parallel series were examined: one that 
contained the C7 piperazinyl ring of ciprofloxacin, and one that contained the C7 diazabicyclononyl 
ring of moxifloxacin.  
 The first set of experiments examined drug effects against wild-type gyrase. In general, the 
inclusion of a C8 substituent enhanced quinolone activity (Figure 6, top left). For the ciprofloxacin-
based series, the compound with a C8 methoxy group generated the highest level of DNA cleavage 
activity. Compared to ciprofloxacin, 8-methoxy-cipro induced ~50% more cleavage at 100 µM drug 
and displayed a potency that was ~2-fold higher (based on the drug concentration required to induce 
50% of the cleavage generated at 100 µM drug). The presence of a C8 methyl group enhanced DNA 
cleavage, but to a lesser extent than did the methoxy group.  
 A more dramatic effect was seen when the C8 methoxy group of moxifloxacin was replaced 
with a methyl group. Compared to moxifloxacin (the fluoroquinolone most commonly used to treat 
tuberculosis) (2, 4-6), 8-methyl-moxi induced ~2-fold more cleavage at 100 µM drug and was ~2-
fold more potent. Furthermore, only 10 µM 8-methyl-moxi was required to induce the same level of 
scission (~30%) as was seen with 100 µM moxifloxacin. In contrast, 8-H-moxi displayed an activity 
similar to that of moxifloxacin. 
 The second set of experiments examined the effects of the C8 substituent on fluoroquinolone 
activity against the resistant GyrAA90V and GyrAD94G mutant enzymes (Figure 6, top right and 
bottom left, respectively). When the function of the water-metal ion bridge was disrupted, the C8 
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substituent had a much greater influence on drug activity. Drugs lacking a C8 substituent 
(ciprofloxacin and 8-H-moxi) showed little activity against either fluoroquinolone-resistant enzyme. 
However, in the presence of either a C8 methyl or methoxy substituent, high levels of activity were 
maintained. To this point, 8-methyl-moxi displayed nearly wild-type activity against GyrAA90V. 
Moreover, even though its activity against GyrAD94G was decreased, 8-methyl-moxi still induced 
higher levels of cleavage than did moxifloxacin with wild-type gyrase. Representative gels showing 
the effects of moxifloxacin and 8-methyl-moxi on DNA cleavage mediated by the mutant GyrAD94G 
enzyme are shown in Supplemental Figure S2. 
 Some fluoroquinolones and related compounds that display high activity against resistant 
bacterial type II topoisomerases cross-react with human topoisomerase IIα, excluding them from 
clinical development as antibacterial drugs. For example, CP-115,955 induces higher levels of 
cleavage with the human enzyme than does etoposide, a commonly prescribed anticancer drug (45, 
46) (Figure 6, bottom right). Notably, none of the ciprofloxacin- or moxifloxacin-based compounds 
employed in this study displayed significant activity against human topoisomerase IIα.  
 To further understand the contributions of the C7 and C8 substituents to quinolone activity, we 
determined the abilities of the two least effective compounds (ciprofloxacin and 8-H-moxi) to 
compete with the two most effective drugs (8-methoxy-cipro and 8-methyl-moxi) (Figure 7, left and 
right, respectively). The GyrAA90V and GyrAD94G mutant enzymes were used so that the 
contributions of the C7 and C8 groups would not be obscured by the water-metal ion bridge. A 
representative gel showing the effects of ciprofloxacin and 8-H-moxi on DNA cleavage mediated 
by the GyrAD94G mutant gyrase in the presence of 50 µM 8-methoxy-cipro is shown in 
Supplemental Figure S3. Three observations were noted. First, the concentrations of ciprofloxacin 
and 8-H-moxi required to compete out 50% of the DNA cleavage induced by 50 µM 8-methyl-cipro 
or 8-methyl-moxi were 100 µM or higher. This finding (which is consistent with the potency data 
discussed for Figure 6) indicates that the C8-H derivatives display a decreased affinity for the 
enzymes as compared to 8-methoxy-cipro and 8-methyl-moxi. Thus, a C8 group appears to 
contribute to drug binding within the enzyme-DNA cleavage complex. Second, compounds bearing 
a C7 diazabicyclononyl group (as found in moxifloxacin) competed better than those with a C7 
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piperazinyl substituent (as found in ciprofloxacin), suggesting that moxifloxacin- as opposed to 
ciprofloxacin-based analogs interact more tightly with M. tuberculosis gyrase. Third, each 
compound competed less effectively against 8-methyl-moxi than against 8-methoxy-cipro, 
indicating that 8-methyl-moxi interacts more tightly with the enzyme. This finding is consistent 
with the observation that 8-methyl-moxi induced higher levels of DNA cleavage with all of the 
enzymes tested than did the other fluoroquinolones in these two series (see Figure 6). 
 Finally, to further examine the contributions of the C7 and C8 substituents to quinolone action, 
we determined the persistence of cleavage complexes formed in the presence of ciprofloxacin, 
moxifloxacin, 8-methoxy-cipro, and 8-methyl-moxi (Figure 8). Moxifloxacin induced more stable 
cleavage complexes than ciprofloxacin with all three enzymes. This finding is consistent with 
binding studies (47) suggesting that moxifloxacin binds more tightly than ciprofloxacin to M. 
tuberculosis gyrase. Furthermore, consistent with the competition experiments, compounds 
containing the C7 diazabicyclononyl group of moxifloxacin induced cleavage complexes that were 
more stable than those formed with the C7 piperazinyl group of ciprofloxacin with both the wild-
type and resistant enzymes. Lastly, in all cases, 8-methyl-moxi induced the most stable cleavage 
complexes. Once again, this finding correlates with the high activity of 8-methyl-moxi. 
 Summary. As fluoroquinolones become more important for the treatment of tuberculosis and 
resistance becomes more prevalent, there is a critical need to understand the binding interactions 
and mechanistic details of quinolone-based agents with M. tuberculosis gyrase in order to develop 
new agents with high activity against wild-type and resistant disease. Thus, we analyzed 
interactions between quinolone-based agents and wild-type M. tuberculosis gyrase and resistant 
mutants. The interaction of current fluoroquinolones with gyrase is governed predominately by a 
critical water-metal ion bridge. However, in contrast to most bacterial type II enzymes, M. 
tuberculosis gyrase uses only one amino acid to anchor the bridge. The most common resistance-
conferring mutations in gyrase disrupt the bridge interaction between fluoroquinolones and the 
enzyme. When bridge function is compromised, resistance can be overcome, at least in part, by the 
introduction of specific groups at the C7 and C8 positions. By dissecting fluoroquinolone-enzyme 
interactions, we determined that an 8-methyl derivative of moxifloxacin induces high levels of 
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stable cleavage complexes with wild-type and common fluoroquinolone-resistant mutant enzymes. 
This chemical biology approach to understanding the basis for fluoroquinolone-enzyme interactions 
has the potential to guide the future development of novel agents with improved activity against 
tuberculosis. 
Methods 
Materials and Enzymes. Ciprofloxacin and moxifloxacin were obtained from LKT Laboratories. 
8-Methyl-cipro, 8-methoxy-cipro, 8-H-moxi, 8-methyl-moxi, 8-H-3’-(AM)P-FQ, 8-H-3’-(AM)P-
dione, 8-methyl-3’-(AM)P-FQ, and 8-methyl-3’-(AM)P-dione were synthesized as reported 
previously (32). Ciprofloxacin-based compounds were stored at -20 °C as 40 mM stock solutions in 
0.1 N NaOH and diluted five-fold with 10 mM Tris–HCl (pH 7.9) immediately prior to use. All 
other compounds were stored at 4 °C as 20 mM stock solutions in 100% DMSO. Supplementary 
Table S1 contains the full chemical, library, and abbreviated names for the compounds used in this 
study. Other chemicals were analytical reagent grade. 
 The coding regions for residues 2-675 of GyrB and 2-838 of GyrA from M. tuberculosis were 
amplified from genomic DNA (American Type Culture Collection strain H37Rv) and individually 
cloned into a pET-28b derivative containing an N-terminal, tobacco etch virus (TEV) protease-
cleavable hexahistidine tag. Mutant GyrA vectors were generated by QuikChange (Agilent). 
Proteins were overexpressed in E. coli strain Rosetta 2 pLysS (EMD Millipore) by growing cells at 
30 °C until log phase, then inducing with 1 mM isopropyl-β-D-thiogalactopyranoside for 3 h. Cells 
were harvested by centrifugation and resuspended in buffer A [20 mM Tris–HCl (pH 7.9), 500 mM 
NaCl, 5 mM imidazole, and 10% glycerol with protease inhibitors], then frozen drop wise in liquid 
nitrogen.  
 Cells were sonicated and centrifuged, and the clarified lysate was passed over a HisTrap HP 
column (GE Healthcare). His-tagged protein was eluted with buffer B [20 mM Tris–HCl (pH 7.9), 
500 mM NaCl, 250 mM imidazole, and 10% glycerol with protease inhibitors], then concentrated 
and exchanged into buffer A overnight at 4 °C, in the presence of His-tagged TEV protease. This 
mixture was passed over a HisTrap HP column, and the flow-through was collected, concentrated, 
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and run over an S-300 gel filtration column (GE Healthcare) in buffer C [50 mM Tris–HCl (pH 
7.9), 500 mM KCl, 2 mM β-mercaptoethanol, and 10% glycerol]. Peak fractions were pooled, 
concentrated, and diluted into a high-glycerol variant of buffer C, so that the final glycerol 
concentration reached 30% prior to storage at -80 °C.  
 Human topoisomerase IIα was expressed in yeast and purified as described by Kingma et al. 
(48). 
 Negatively supercoiled pBR322 plasmid DNA was prepared from E. coli using a Plasmid 
Mega Kit (Qiagen) as described by the manufacturer. Relaxed pBR322 plasmid DNA was 
generated by treatment with topoisomerase I for 30 min as previously described (49), followed by 
phenol-chloroform-isoamyl alcohol extraction, ethanol precipitation, and resuspension in 5 mM 
Tris-HCl (pH 8.5) and 500 µM EDTA. 
DNA Supercoiling. DNA supercoiling reactions (20 µL) contained 25 nM wild-type or mutant 
gyrase and 5 nM relaxed pBR322 in reaction buffer [10 mM Tris–HCl (pH 7.5), 40 mM KCl, 0.1 
mg/mL BSA, 6 mM MgCl2, 10% (v/v) glycerol, and 0.5 mM DTT] supplemented with 1 mM ATP 
and were incubated at 37 °C. DNA supercoiling was stopped at times from 0–45 min by the 
addition of 3 µL of 0.77% SDS and 77.5 mM EDTA. Samples were mixed with 2 µL of agarose gel 
loading buffer [60% sucrose, 10 mM Tris–HCl (pH 7.9), 0.5% bromophenol blue, and 0.5% xylene 
cyanol FF], heated at 45 °C for 5 min, and subjected to electrophoresis in 1% agarose gels in 100 
mM Tris–borate (pH 8.3) and 2 mM EDTA. Gels were stained with 0.75 µg/mL ethidium bromide 
for 30 min. DNA bands were visualized with medium-range ultraviolet light and quantified using an 
Alpha Innotech digital imaging system. 
DNA Cleavage. DNA cleavage reactions were carried out using the procedure of Fortune and 
Osheroff as adapted by Aldred et al. (20, 50). Reactions with the bacterial enzyme contained 100 
nM wild-type or mutant gyrase and 10 nM negatively supercoiled pBR322 in a total of 20 µL of 
reaction buffer. Reactions with the human enzyme contained 110 nM human topoisomerase IIα and 
10 nM negatively supercoiled pBR322 in a total of 20 µL of 10 mM Tris–HCl (pH 7.9), 5 mM 
MgCl2, 100 mM KCl, 100 µM EDTA, 25 µM dithiothreitol, and 2.5% (v/v) glycerol. All reaction 
mixtures were incubated at 37 °C for 10 min, and enzyme-DNA cleavage complexes were trapped 
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by the addition of 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 8.0). Proteinase K (2 
µL of a 0.8 mg/mL solution) was added, and samples were incubated at 45 °C for 45 min to digest 
the enzyme. Samples were mixed with 2 µL of agarose gel loading buffer, heated at 45 °C for 5 
min, and subjected to electrophoresis in 1% agarose gels in 40 mM Tris–acetate (pH 8.3) and 2 mM 
EDTA containing 0.5 µg/mL ethidium bromide. DNA bands were visualized as described above. 
DNA cleavage was monitored by the conversion of supercoiled plasmid to linear molecules.  
 Assays that monitored gyrase-mediated DNA cleavage in the absence of drugs substituted 6 
mM CaCl2 for 6 mM MgCl2 in the reaction buffer. Assays that assessed DNA cleavage in the 
presence of drugs contained 0–100 µM compound. In some reactions, the concentration dependence 
of MgCl2 was examined or the divalent metal ion was replaced with 2.5 mM MnCl2. 
 For assays that monitored competition between two drugs, the compounds were added 
simultaneously to reaction mixtures, and the final concentrations of the compounds are indicated. In 
these competition assays, the level of cleavage seen with the corresponding concentration of the 
competing drug (in the absence of the drug held at a constant concentration) was used as a baseline 
and was subtracted from the cleavage level seen in the presence of both compounds. 
Persistence of Gyrase-DNA Cleavage Complexes. The persistence of gyrase-DNA cleavage 
complexes established in the presence of drugs was determined using the procedure of Gentry et al. 
as adapted by Aldred et al. (20, 51). Initial reaction mixtures contained 500 nM wild-type or mutant 
gyrase, 50 nM DNA, and 100 µM ciprofloxacin, 50 µM 8-methoxy-cipro, 50 µM moxifloxacin, or 
10 µM 8-methyl-moxi in a total of 20 µL of reaction buffer. Quinolone concentrations that yielded 
similar levels of DNA cleavage were used. Reaction mixtures were incubated at 37 ºC for 10 min 
and then diluted 20–fold with reaction buffer warmed to 37 ºC. Samples (20 µL) were removed at 
times ranging from 0–60 min for the mutant enzymes or 0–180 min for the wild-type enzyme, and 
DNA cleavage was stopped with 2 µL of 5% SDS followed by 2 µL of 250 mM EDTA (pH 8.0). 
Samples were digested with proteinase K and processed as described above for DNA cleavage 
assays. Levels of DNA cleavage were set to 100% at time zero, and the persistence of cleavage 
complexes was determined by the loss of the linear reaction product over time. 
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FIGURE LEGENDS 
Figure 1. Catalytic and DNA cleavage activities of wild-type and mutant M. tuberculosis gyrase in 
the absence of drugs. The ability of wild-type (WT, black), GyrAA90S (A90S, blue), GyrAA90V 
(A90V, red), GyrAD94H (D94H, green), and GyrAD94G (D94G, yellow) to supercoil relaxed pBR322 
plasmid DNA is shown on the left. Gels are representative of three independent experiments. The 
positions of negatively supercoiled [(-)SC] and relaxed (Rel) DNA controls are indicated. The 
ability of the enzymes to cleave negatively supercoiled pBR322 plasmid DNA is shown on the 
right. Error bars represent the standard deviation of at least three independent experiments. 
Figure 2. Drug-induced DNA cleavage mediated by wild-type and mutant M. tuberculosis gyrase. 
The ability of wild-type (WT, black), GyrAA90S (A90S, blue), GyrAA90V (A90V, red), GyrAD94H 
(D94H, green), and GyrAD94G (D94G, yellow) to mediate DNA cleavage in the presence of the 
clinically used fluoroquinolones ciprofloxacin and moxifloxacin (top left and right, respectively), 
the experimental quinazolinediones 8-methyl-3’-(AM)P-dione and 8-H-3’-(AM)P-dione (middle 
left and bottom left, respectively), and the experimental fluoroquinolones 8-methyl-3’-(AM)P-FQ 
and 8-H-3’-(AM)P-FQ (middle right and bottom right, respectively) is shown. Compound structures 
are shown in or above their respective panels. Error bars represent the standard deviation of at least 
three independent experiments.  
Figure 3. Effects of Mg2+ concentration on DNA cleavage mediated by wild-type and mutant M. 
tuberculosis gyrase. Results are shown for 10 µM ciprofloxacin (left) and 10 µM 8-methyl-3’-
(AM)P-dione (right) with wild-type (WT, black), GyrAA90S (A90S, blue), and GyrAA90V (A90V, 
red). DNA cleavage for each drug-enzyme pair was normalized to 100% at 6 mM Mg2+ to facilitate 
direct comparisons. Error bars represent the standard deviation of at least three independent 
experiments. 
Figure 4. Effects of Mn2+ on drug-induced DNA cleavage mediated by wild-type and mutant M. 
tuberculosis gyrase. Results are shown for cleavage mediated by wild-type (WT, black), GyrAA90S 
(A90S, blue), and GyrAA90V (A90V, red) in the presence of ciprofloxacin. Assays included 2.5 mM 
Mn2+, the concentration that yielded maximal enzyme activity, instead of Mg2+. Error bars represent 
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the standard deviation of at least three independent experiments. 
Figure 5. Ability of ciprofloxacin to compete out DNA cleavage induced by 10 µM 8-methyl-3’-
(AM)P-dione with mutant M. tuberculosis gyrase. Results are shown for GyrAA90V (A90V, red) and 
GyrAD94G (D94G, yellow). Both drugs were added to reaction mixtures simultaneously. The low 
level of cleavage seen in the presence of ciprofloxacin alone was used as a baseline and was 
subtracted from DNA scission observed in the presence of both drugs. The level of DNA cleavage 
observed in the presence of the quinazolinedione alone was set to 1.0 to facilitate direct 
comparisons. Error bars represent the standard deviation of at least three independent experiments. 
Figure 6. Effects of ciprofloxacin- and moxifloxacin-based fluoroquinolones on DNA cleavage 
mediated by wild-type and mutant M. tuberculosis gyrase and human topoisomerase IIα. The ability 
of wild-type (WT, top left), GyrAA90V (A90V, top right), and GyrAD94G (D94G, bottom left) gyrase 
and human topoisomerase IIα (hTIIα, bottom right) to cleave DNA in the presence of 
fluoroquinolones containing a C8–H (black), –methyl (blue), or –methoxy (red) group and a C7 
piperazinyl (closed) or diazabicyclononyl (open) group is shown. For human topoisomerase IIα, 
DNA cleavage levels induced by the enzyme in the presence of CP-115,955 or etoposide (dashed 
lines) are shown for comparison. These latter data are from Aldred et al. (32). The ciprofloxacin and 
moxifloxacin fluoroquinolone cores are shown at the top. Error bars represent the standard 
deviation of at least three independent experiments. 
Figure 7. Ability of fluoroquinolones with a C8-H to compete out DNA cleavage induced by 50 
µM 8-methoxy-cipro or 8-methyl-moxi with mutant M. tuberculosis gyrase. Results are shown for 
GyrAA90V (A90V, black) and GyrAD94G (D94G, blue). Ciprofloxacin (Cipro, closed) or 8-H-moxi 
(open) and 8-methoxy-cipro (left) or 8-methyl-moxi (right) were added to reaction mixtures 
simultaneously. The low level of cleavage seen in the presence of the C8-H fluoroquinolones alone 
was used as a baseline and was subtracted from the DNA scission observed in the presence of both 
drugs. The level of DNA cleavage observed in the presence of 8-methoxy-cipro or 8-methyl-moxi 
alone was set to 1.0 to facilitate direct comparisons. Error bars represent the standard deviation of at 
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least three independent experiments. 
Figure 8. Effects of fluoroquinolones on the persistence of cleavage complexes formed by wild-
type and mutant M. tuberculosis gyrase. The stability of ternary enzyme-drug-DNA cleavage 
complexes formed with wild-type (WT, left), GyrAA90V (A90V, middle), and GyrAD94G (D94G, 
right) was determined in the presence of 100 µM ciprofloxacin (Cipro, black), 50 µM moxifloxacin 
(Moxi, blue), 50 µM 8-methoxy-cipro (red), or 10 µM 8-methyl-moxi (yellow). The data table 
(inset, middle) lists the t1/2 of DNA cleavage complexes formed with each drug-enzyme 
combination. Initial DNA cleavage-religation reactions were allowed to come to equilibrium and 
were then diluted 20-fold with reaction buffer. Levels of DNA cleavage at time zero were set to 
100%. Error bars represent the standard deviation of at least three independent experiments. 
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Supplementary Table S1. Full chemical, library, and abbreviated names of compounds 
used in this study. 
Supplementary Figure S2. Effects of moxifloxacin (top) and 8-methyl-moxi (bottom) on 
DNA cleavage mediated by wild-type (left) and GyrAD94G mutant gyrase (right). The 
positions of nicked (single-stranded breaks), linear (double-stranded breaks), and the 
negatively supercoiled (SC) substrate are indicated. Ethidium bromide-stained agarose 
gels are shown and are representative of three independent experiments. 
Supplementary Figure S3. Ability of 50 or 100 µM ciprofloxacin (Cipro) or 50 or 100 µM 
8-H-moxifloxacin (8-H-Moxi) to compete out DNA cleavage induced by 50 µM 8-
methoxy-cipro with mutant GyrAD94G M. tuberculosis gyrase. Cipro or 8-H-moxi and 8-
methoxy-cipro were added to reaction mixtures simultaneously. The low level of 
cleavage seen in the presence of cipro or 8-H-moxi alone is shown at right. Ethidium 
bromide-stained agarose gels are shown and are representative of three independent 
experiments. 
Name used in this study Library name Chemical name 
Ciprofloxacin 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methyl-cipro UILI-2-89 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methoxy-cipro UIHS-IIa-101 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid 
Moxifloxacin 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-
3-quinolinecarboxylic acid 
8-Methyl-moxi UIHS-IIa-45 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-
quinolinecarboxylic acid 
8-H-moxi UIHS-IIa-239 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-
quinolinecarboxylic acid 
CP-115,955 CP-115,955 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(4-hydroxyphenyl)-4-oxo-3-quinolinecarboxylic acid 
8-Methyl-3'-(AM)P-FQ UIHS-I-303 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-4-oxo-3-
quinolinecarboxylic acid 
8-Methyl-3'-(AM)P-dione UIJR1-048,   
Lot UILI-2-95 
3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-8-methyl-2,4(1H,3H)-
quinazolinedione 
8-H-3'-(AM)P-FQ UIHS-IIIa-35 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-4-oxo-3-quinolinecarboxylic acid 
8-H-3'-(AM)P-dione UIHS-IIa-245 3-amino-7-[(3S)-3-(aminomethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-2,4(1H,3H)-quinazolinedione 
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